Income statement
CNY
Annual
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 186M | 212M | 260M | 214M |
| Gross Profit | 91M | 130M | 154M | 125M |
| Operating Income | 16M | 45M | 66M | 52M |
| EBITDA | 43M | 72M | 86M | 70M |
| Net Income | 11M | 31M | 47M | 39M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.75
-3.23% today
1Y Change
-89.16%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zhengye Biotechnology Holding Limited (ZYBT) is a Healthcare stock with a market cap of $320.00M and listed on NASDAQ. The stock last traded around $0.75 and down 89.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -37.6%, EPS growth of -100.0%, a dividend yield of 0.0%. What stands out right now is revenue -37.6%, EPS -100.0%, free cash flow -94.7% with operating margin -58.7% and ROIC -17.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZYBT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZYBT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZYBT Max Drawdown
-94.39%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZYBT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$214.1M
-17.8% YoY
FY Net Income
$39.0M
-16.6% YoY
Free Cash Flow
$5.4M
+154.1% YoY
Revenue Growth
-37.6%
EPS Growth
-100.0%
Gross Margin
20.5%
Net Margin
-60.0%
Income statement
CNY
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 186M | 212M | 260M | 214M |
| Gross Profit | 91M | 130M | 154M | 125M |
| Operating Income | 16M | 45M | 66M | 52M |
| EBITDA | 43M | 72M | 86M | 70M |
| Net Income | 11M | 31M | 47M | 39M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
CNY
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 19M | 15M | 10M | 6M |
| Total Assets | 493M | 500M | 520M | 445M |
| Total Liabilities | 141M | 161M | 163M | 126M |
| Shareholder Equity | 284M | 273M | 296M | 267M |
| Total Debt | 86M | 90M | 65M | 30M |
| Net Debt | 68M | 75M | 55M | 24M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
+83.5% YoY
Capital Expenditures
26M
+3.4% YoY
Free Cash Flow
5M
+154.1% YoY
Key ratios
Gross Margin
20.5%
Operating Margin
-58.7%
Net Margin
-60.0%
ROE
-26.1%
Debt / Equity
0.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.